Current Oncology (Sep 2024)

Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume

  • Bediz Kurt İnci,
  • Pınar Kubilay Tolunay,
  • Şura Öztekin,
  • Ergin Aydemir,
  • İrem Öner,
  • Öztürk Ateş,
  • Cengiz Karaçin

DOI
https://doi.org/10.3390/curroncol31100424
Journal volume & issue
Vol. 31, no. 10
pp. 5722 – 5729

Abstract

Read online

Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact of changes in Mean Corpuscular Volume (MCV) on predicting responses to treatment and survival in patients with hormone-receptor-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors and endocrine therapy. Methods: Retrospectively, data on hemoglobin levels, MCV, B12, folate levels, and survival times were collected from 275 patients. Patients were categorized into two groups based on the degree of MCV change (delta MCV ≤ 10 vs. >10). Kaplan–Meier survival analysis was performed, with significance set at p p 10 had a median progression-free survival of 33 months, compared to 23 months for those with MCV delta ≤ 10 (p = 0.029). There was no significant difference in median overall survival times between the two groups (p = 0.158). Conclusion: This study highlights that patients with MCV delta > 10 had longer median progression-free survival compared to those with MCV delta ≤ 10.

Keywords